Thermo Fisher Scientific Inc. $TMO Shares Sold by Truist Financial Corp

Key Points

• Truist trimmed its stake: Truist cut holdings in Thermo Fisher by 2.8% in Q4, selling 3,266 shares to end with 114,171 shares valued at about $66.16 million, while institutional investors own roughly 89.23% of the stock.
• Insiders sold recently: COO Gianluca Pettiti and CEO Marc N. Casper sold a combined 5,800 shares (about $2.96M) in the past three months, leaving insiders with roughly 0.33% ownership.
• Strong results and bullish analyst view: Thermo Fisher beat Q results (EPS $5.44 vs. $5.25; revenue $11.01B vs. $10.86B), provided FY26 EPS guidance of 24.640–25.120, and carries a MarketBeat consensus "Buy" with an average target of $623.05.

Truist Financial Corp cut its holdings in shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 2.8% during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 114,171 shares of the medical research company's stock after selling 3,266 shares during the period. Truist Financial Corp's holdings in Thermo Fisher Scientific were worth $66,156,000 as of its most recent SEC filing.

Other institutional investors have also recently modified their holdings of the company. JPL Wealth Management LLC acquired a new position in shares of Thermo Fisher Scientific during the 3rd quarter worth approximately $28,000. Beacon Financial Strategies CORP acquired a new position in shares of Thermo Fisher Scientific during the 4th quarter worth approximately $29,000. Olistico Wealth LLC acquired a new position in shares of Thermo Fisher Scientific during the 4th quarter worth approximately $29,000. Cloud Capital Management LLC acquired a new stake in shares of Thermo Fisher Scientific in the third quarter valued at about $31,000. Finally, KERR FINANCIAL PLANNING Corp acquired a new stake in shares of Thermo Fisher Scientific in the third quarter valued at about $38,000. 89.23% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other Thermo Fisher Scientific news, COO Gianluca Pettiti sold 400 shares of the business's stock in a transaction on Monday, April 27th. The stock was sold at an average price of $462.66, for a total transaction of $185,064.00. Following the transaction, the chief operating officer owned 25,051 shares of the company's stock, valued at approximately $11,590,095.66. The trade was a 1.57% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Marc N. Casper sold 5,000 shares of the business's stock in a transaction on Wednesday, March 4th. The stock was sold at an average price of $512.40, for a total value of $2,562,000.00. Following the transaction, the chief executive officer directly owned 123,925 shares in the company, valued at $63,499,170. This trade represents a 3.88% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 5,800 shares of company stock worth $2,963,544 in the last three months. 0.33% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

Several brokerages have recently issued reports on TMO. Jefferies Financial Group upgraded shares of Thermo Fisher Scientific to a "strong-buy" rating in a research report on Friday, April 24th. Wall Street Zen upgraded shares of Thermo Fisher Scientific from a "hold" rating to a "buy" rating in a research report on Saturday, February 28th. Robert W. Baird reduced their target price on Thermo Fisher Scientific from $653.00 to $639.00 and set an "outperform" rating for the company in a report on Friday, April 24th. TD Cowen reduced their target price on Thermo Fisher Scientific from $696.00 to $683.00 and set a "buy" rating for the company in a report on Friday, January 30th. Finally, UBS Group reissued a "neutral" rating and set a $615.00 target price on shares of Thermo Fisher Scientific in a report on Friday, January 30th. Two investment analysts have rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and two have given a Hold rating to the company. According to MarketBeat.com, the company currently has a consensus rating of "Buy" and an average target price of $623.05.

Thermo Fisher Scientific Trading Down 1.4%

Shares of TMO opened at $462.46 on Tuesday. The stock has a market cap of $171.86 billion, a PE ratio of 25.42, a price-to-earnings-growth ratio of 2.08 and a beta of 0.88. The company has a quick ratio of 1.15, a current ratio of 1.53 and a debt-to-equity ratio of 0.77. Thermo Fisher Scientific Inc. has a 52-week low of $385.46 and a 52-week high of $643.99. The firm's fifty day moving average is $496.11 and its two-hundred day moving average is $548.03.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last released its quarterly earnings data on Thursday, April 23rd. The medical research company reported $5.44 EPS for the quarter, beating analysts' consensus estimates of $5.25 by $0.19. The company had revenue of $11.01 billion during the quarter, compared to the consensus estimate of $10.86 billion. Thermo Fisher Scientific had a net margin of 15.15% and a return on equity of 16.86%. Thermo Fisher Scientific's quarterly revenue was up 6.2% on a year-over-year basis. During the same quarter in the prior year, the firm earned $5.15 EPS. Thermo Fisher Scientific has set its FY 2026 guidance at 24.640-25.120 EPS. Research analysts forecast that Thermo Fisher Scientific Inc. will post 24.85 earnings per share for the current fiscal year.

Thermo Fisher Scientific Increases Dividend

The business also recently disclosed a quarterly dividend, which was paid on Wednesday, April 15th. Shareholders of record on Friday, March 13th were paid a dividend of $0.47 per share. This represents a $1.88 dividend on an annualized basis and a yield of 0.4%. This is an increase from Thermo Fisher Scientific's previous quarterly dividend of $0.43. The ex-dividend date of this dividend was Friday, March 13th. Thermo Fisher Scientific's dividend payout ratio is presently 10.34%.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific NYSE: TMO is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.

Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.